DE202012006700U1 - coating - Google Patents

Abstract

Functional coating of balloon catheters characterized in that film or lacquer-forming TPGS NF, d-a-tocophery polyethylene glycol are used as a carrier material for antiproliferative, anti-inflammatory and / or antifungal agents z. B. Abciximab, Acemetacin, Acetylvismion B, Aclarubicin, Ademetionin, Adriamycin, Aescin, Afromoson, Akagerin, Aldesleukin, Amidoron, Aminoglutethemid, Amsacrin, Anakinra, Anastrozymocharäure, Anemonin, Aescin, Aritochrombotopteric, AntimychrombarinII , Ascomycin, asparaginase, aspirin, atorvastatin, auranofin, azathioprine, azithromycin, baccatin, bafilomycin, basiliximab, bendamustine, benzocaine, berberine, betulin, betulinic acid, bilobol, bisparthenolidine, bleomycin, bombrestatin and their derivatives , Bryophylline A, busulfan, antithrombin, bivalirudin, cadherine, camptothecin, capecitabine, o-carbamoylphenoxyacetic acid, carboplatin, carmustine, celecoxib, cepharantine, cerivastatin, CETP inhibitors, chlorambucil, chloroicquine phosphate, chlorambucil, chloro-chinophosphate, ciphromycloxacine, ciphromycloxacine, ciphramycloxacin, ciphromisplin, ciphricophosphate, ciphromycloxacin, o-carbamoylphenoxyacetic acid, Concanamycin, Coumadin, C-Type Natriuretic Peptide (CNP), Cudraisoflavone A, Curcumin, Cyclophosphamide, Cyclos porin A, cytarabine, dacarbazine, daclizumab, dactinomycin, dapsone, daunorubicin, diclofenac, 1,11-dimethoxycanthin-6-one, docetaxel, doxorubicin, dunaimycin, epirubicin, epothimolg, etstrosidycin, everimolone A and Brast, erytobusidycin, etstrosidycin, epothimolg, etstrosidycin Fluroblastin, Fluvastatin, Fludarabin, Fludarabin-5'-dihydrogen phosphate, Fluorouracil, Folimycin, Fosfestrol, Gemcitabine, Ghalakinosid, Ginkgol, ...

Description

The invention relates to a coating of carrier material on balloon catheter, in particular PTCA catheters, which contain film or paint-forming TPGS NF, α-tocopherol polyethylene glycol alone or in combination with further materials as coating material, the other materials comprising organic compounds, such as lipids, vitamins or their components, and inorganic compounds belonging to the substance group of the oxides or salts, and the coating material may optionally contain application-specific additives. Such balloon coatings can be used in the human and veterinary fields but especially in cardiology areas.

TPGS NF, d-α-Tocophery Polyethylene glycols have the property to adhere well to surfaces, to be abrasion resistant and to be readily miscible with other materials. TPGS NF, d-α-Tocophery Polyethylene glycols have therefore found a wide range of applications in addition to purely technical applications as a coating material for orally administered drugs, nutritional supplements and cosmetics. In the cosmetic field, numerous applications in the dermatological field of TPGS NF, d-α-tocopherol polyethylene glycol are published. Furthermore, some methods for producing a surface coating of powder, granules or tablets containing active ingredients, in particular selective proteins, are described in order to achieve a release only in the duodenum and not in the stomach. In the materials used in addition to the usual synthetic TPGS NF, d-α-tocopherol called polyethylene glycol. The object of the present invention is to supply the substance group of TPGS NF, α-tocopherol polyethylene glycol to a new type of application as a coating material for balloon catheters, in particular PTCA catheters. The physical and antibacterial properties are exploited here as well as the typical release properties. In this case, the coating material may contain further components which influence the functional properties of the balloon coating and / or are physiologically relevant. This task of producing functional coatings on balloon catheters, in particular PTCA catheters in the human and veterinary field, is achieved according to the invention by using film-forming or lacquer-forming TPGS NF, α-tocopherol polyethylene glycol alone or in combination with other materials be, the other materials may be organic or inorganic nature. The TPGS NF, d-α-tocopherol polyethylene glycol materials may be of either natural or synthetic or semisynthetic origin. In the case of the inorganic materials used in combination, in particular vitamins, oxides or salts or mixtures thereof are of interest. the salts to be used are phosphates, sulfates, silicates, carbonates or corresponding mixtures. In the case of the organic materials used in combination, in particular lipids and their components are of greater importance. This also applies to carboxylic acids, their derivatives and substitution products. It has been found that in particular the TPGS NF, α-tocopherol polyethylene glycols have, on their own or in their naturally occurring form, the desired physicochemical properties as coating material for balloon catheters. The addition of lipids, carboxylic acids and their derivatives causes a positive change in the elasticity of the coating. The produced balloon coating becomes more elastic and thus less brittle. The addition of inorganic materials, preferably from the series of phosphates, sulfates, silicates, carbonates or mixtures thereof, plays a special role in the ingrowth of the implants and is intended to induce growth stimulation by the provision of appropriate ions. Optionally, an application-specific additive may be added to the base material TPGS NF, α-tocopherol polyethylene glycol, organic or inorganic additive. The addition of an additive may also be in the form of solid nano- or microparticles or capsules. In addition to the direct addition of bioactive substances, such as antibiotics, cytostatics, hormones or growth factors or a combination of these substance classes, the bioactive substances can also be used immobilized. As is known, a direct release via the balloon catheter of the active substances can be achieved via the manner of the immobilization / encapsulation. The procedural implementation of the production of the coating begins with the TPGS NF, α-tocopherol polyethylene glycol component being converted into a homogeneous solution. Preferred are lower alcohols, ketones and esters, in many cases ethanol is used. After adjustment of the desired concentration, the inorganic or organic materials and optionally an application-specific additive are added. If all components are combined, homogenization takes place depending on the viscosity of the mass by means of different stirring techniques (stirrers, dispersing agents). The coating solution can be z. B. pour out, squeeze, squirt or spray. Furthermore, by dipping or by reducing the pressure, the coating material can be applied to the surface of the balloon catheter. The application is not only limited to static surfaces, but also expandable to rotating balloon catheters. For coating with TPGS NF, α-tocopherol polyethylene glycol, natural or synthetic materials are suitable for use with a balloon catheter, regardless of their roughness, pre-treatment or precoating. The present balloon coating with film-forming or TPGS NF, α-tocopherol polyethylene glycol ensures both the protection of the balloon catheter, but also opens up the possibility of functionally effective. This functional aspect relates to material properties, such as strength and elasticity of the coating and the effects emanating from the coating, such. B. antibacterial effects. The application-specific additives allow a broad pharmacological effect of the coating. The strength and elasticity are particularly favorable conditions for the use of the balloon catheter. The invention will be described in more detail with reference to the following embodiment without being limited thereto.

EXAMPLES

Example 1:

5 g of TPGS NF, α-tocopherol polyethylene glycol are dissolved in 100 ml of ethanol with stirring for 24 h. To this solution is added 2% stearin (w / w). it is allowed to stir for a further 4 h at 30 ° C. The balloon catheters are immersed in this solution. By repeated dipping the desired layer thickness of approx. 0.5 μg / mm ² balloon is reached. The mixture is then dried at 40 ° C for 1 h. (This layer acts as a carrier material for a cytostatic eg Paclitaxel) After drying, Nanocrystalline Packlitaxel is preferably applied to the carrier matrix (surface) by means of immersion or spraying. B. TPGS NF, d-α-tocopherol polyethylene glycol.

Example 2:

5 g of TPGS NF, α-tocopherol polyethylene glycol are dissolved in 100 ml of ethanol with stirring for 24 h. The solution is applied to the balloon catheter by means of a spray technique. Subsequently, a cytostatic agent is applied or introduced onto the TPGS NF, α-tocopherol polyethylene glycol suspension in a dipping or spraying process. The cytostatic z. B. Paclitaxel is released after a few minutes (0.5-2 min).

Claims (17)

Functional coating of balloon catheter characterized in that as a coating material film or paint-forming TPGS NF, da-tocopherol polyethylene glycol are used for themselves as a support material for antiproliferative, anti-inflammatory and / or antifungal agents such. Abciximab, acemetacin, acetylvismion B, aclarubicin, ademetionin, adriamycin, aescin, afromosone, akagerin, aldesleukin, amidorone, aminoglutethemide, amsacrine, anakinra, anastrozole, anemonin, anopterin, antifungals, antithrombotics, apocymarin, argatroban, aristolactam AII, aristolochic acid , Ascomycin, asparaginase, aspirin, atorvastatin, auranofin, azathioprine, azithromycin, baccatin, bafilomycin, basiliximab, bendamustine, benzocaine, berberine, betulin, betulinic acid, bilobol, bisparthenolidine, bleomycin, bombrestatin, boswellic acids and their derivatives, bruceanols A, B and C , Bryophyllin A, busulfan, antithrombin, bivalirudin, cadherins, camptothecin, capecitabine, o-carbamoylphenoxyacetic acid, carboplatin, carmustine, celecoxib, cepharantin, cerivastatin, CETP inhibitors, chlorambucil, chloroquine phosphate, cictoxin, ciprofloxacin, cisplatin, cladribine, clarithromycin, colchicine, Concanamycin, coumadin, C-type Natriuretic Peptide (CNP), cudraisoflavone A, curcumin, cyclophosphamide, Cy closporin A, cytarabine, dacarbazine, daclizumab, dactinomycin, dapsone, daunorubicin, diclofenac, 1,11-dimethoxycanthin-6-one, docetaxel, doxorubicin, dunaimycin, epirubicin, epothilones A and B, erythromycin, estramustine, etoboside, everolimus, filgrastim, Fluroblastin, fluvastatin, fludarabine, fludarabine 5'-dihydrogen phosphate, fluorouracil, folimycin, fosfestrol, gemcitabine, ghalacinoside, ginkgol, ginkgolic acid, glycoside 1a, 4-hydroxyoxycyclophosphamide, idarubicin, ifosfamide, josamycin, lapachol, lomustine, lovastatin, melphalan, midecamycin, Mitoxantrone, nimustine, pitavastatin, pravastatin, procarbazine, mitomycin, methotrexate, mercaptopurine, thioguanine, oxaliplatin, irinotecan, topotecan, hydroxycarbamide, miltefosine, pentostatin, pegasparase, exemestane, letrozole, formestan, SMC proliferation inhibitor-2w, mitoxanthrone, mycophenolate mofetil, c-myc antisense, [beta] -myc antisense, [beta] -lapachone, podophyllotoxin, podophyllic acid-2-ethyl hydrazide, molgramostim (rhuGM-CSF), peginterferon [alp ha] -2b, lanograstim (r -HuG-CSF), macrogol, selectin (cytokine antagonist), cytokine inhibitors, COX-2 inhibitor, NFkB, angiopeptin, monoclonal antibodies that inhibit muscle cell proliferation, bFGF antagonists, probucol, prostaglandins, 1 Hydroxy-11-methoxycanthin-6-one, scopolectin, NO donors such as pentaerythrityl tetranitrate and syndnoeimines, S-nitrosated derivatives, tamoxifen, staurosporine, [beta] estradiol, [alpha] estradiol, estriol, estrone, ethinylestradiol, medroxyprogesterone, estradiol cypionates , Estradiol benzoates, tranilast, kamebakaurin and other terpenoids used in cancer therapy, verapamil, tyrosine kinase inhibitors (tyrphostins), paclitaxel and its derivatives, such as 6- [alpha] -hydroxy-paclitaxel, taxotere, carbonic suboxide (MCS) and its macrocyclic oligomers, mofebutazone, lonazolac, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, penicillamine, hydroxychloroquine, sodium aurothiomalate, oxaceprol, [beta] -sitosterol, myrtainaine, polidocanol, Nonivami d, Levomenthol, ellipticin, D-24851 (Calbiochem), colcemid, cytochalasin A-E, indanocine, nocadazole, S 100 protein, bacitracin, vitronectin receptor antagonist, azelastine, guanidyl cyclase stimulator, tissue protease inhibitor of metalloproteinase-1 and 2, free nucleic acids, nucleic acids incorporated into virus carriers, DNA and RNA fragments, Plaminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, Antisense Oligonucleotides, VEGF inhibitors, IGF-1, drugs from the group of antibiotics such as Cefadroxil, Cefazolin, Cefaclor, Cefotixin Tobramycin, gentamycin, penicillins such as dicloxacillin, oxacillin, sulfonamides, metronidazole, enoxoparin, desulfated and N-reacetylated heparin (Hemoparin <(R)>), tissue plasminogen activator, GpIIb / IIIa platelet membrane receptor, factor Xa inhibitor antibody, heparin , Hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyramidol, trapidil, nitroprusside, PDGF antagonists like Triaz olopyrimidine and seramin, ACE inhibitors such as captopril, cilazapril, lisinopril, enalapril, losartan, thioprotease inhibitors, prostacyclin, vapiprost, interferon [alpha], [beta] and [gamma], histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators such as p65, NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, nifedipine, tocopherol tranilast, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, leflunomide, etanercept, sulfasalazine, etoposide, dicloxacylline, tetracycline, triamcinolone, mutamycin, procainimide, retinoic acid, quinidine, disopyrimide, flecainide, Propafenone, sotolol, natural and synthetic steroids such as inotodiol, maquiroside A, ghalakinoside, mansonine, strebloside, hydrocortisone, betamethasone, dexamethasone, nonsteroidal substances (NSAIDS) such as fenoporfen, ibuprofen, indomethacin, naproxen, phenylbutazone and other antiviral agents such as acyclovir, ganciclovir and zidovudine, clotrimazole, flucytosine, griseofulvin, Ketoconazole, miconazole, nystatin, terbinafine, antiprozoal agents such as chloroquine, mefloquine, quinine, and also natural terpenoids such as hippocaesculin, barringtogenol C21 angelate, 14-dehydroagrostistachine, agroscerin, agrostistachin, 17-hydroxyagrostistachine, ovatodiolide, 4,7-oxycycloanisomic acid, Baccharinoids B1, B2, B3 and B7, Tubeimoside, Bruceantinoside C, Yadanzioside N, and P, Isodeoxyelephantopin, Tomenphantopin A and B, Coronarin A, B, C and D, Ursolic Acid, Hyptate Acid A, Iso-Iridogermanal. Maytenfoliol, Effusantin A, Excisanin A and B, Longikaurin B, Sculponeatin C, Kamebaunin, Leukamenin A and B, 13,18-Dehydro-6-alpha-Senecioyloxychaparrin, Taxamairin A and B, Regenilol, Triptolide, Cymarin, Hydroxyanopterin, Protoanemonin, cheliburine chloride, sinococulin A and B, dihydronitidine, nitidine chloride, 12-beta-hydroxypregnadiene 3,20-dione, helenaline, indicin, indicin-N-oxide, lasiocarpine, inotodiol, podophyllotoxin, justicidin A and B, larreatine, malloterine, mallotochromanol , Isobutyrylmallotochromanol, maquiroside A, marchantin A, maytansine, lycoridicin, margetin, pancratistatin, liriodenin, bispsrthenolidine, oxoushinsunin, periplocoside A, ursolic acid, deoxypypsorospermine, psycorubin, ricin A, sanguinarine, manuwic acid, methylsorbifolin, sphatheliachromes, stizophyllin, mansonine, strebloside, dihydrousambaraensin , Hydroxyusambarin, Strychnopentamine, Strychnophyllin, Usambarin, Usambarensin, Liriodenin, Oxoushinsunin, Daphnoretin, Lariciresinol, Methoxylariciresinol, S yringaresinol, sirolimus (rapamycin), somatostatin, tacrolimus, roxithromycin, troleandomycin, simvastatin, rosuvastatin, vinblastine, vincristine, vindesine, teniposide, vinorelbine, tropfosfamide, treosulfan, tremozolomide, thiotepa, tretinoin, spiramycin, umbelliferone, deacetylvismion A, vismion A and B , Zeorin and vitamins of any kind. As antiproliferative agents preferably cytostatics, macrolide antibiotics, and / or statins are used. Suitable antiproliferative agents are sirolimus (rapamycin), everolimus, pimecrolimus, somatostatin, tacrolimus, roxithromycin, dunaimycin, ascomycin, bafilomycin, erythromycin, midecamycin, josamycin, concanamycin, clarithromycin, troleandomycin, folimycin, cerivastatin, simvastatin, lovastatin, fluvastatin, rosuvastatin, atorvastatin , Pravastatin, pitavastatin, vinblastine, vincristine, vindesine, vinorelbine, etoboside, teniposide, nimustine, carmustine, lomustine, cyclophosphamide, 4-hydroxyoxycyclophosphamide estramustine, melphalan, betulinic acid, camptothecin, lapachol, [beta] -lapachone, podophyllotoxin, betulin, tropfosfamide, Podophyllic Acid 2-Ethylhydrazide, Ifosfamide, Chlorambucil, Bendamustine, Dacarbazine, Busulfan, Procarbazine, Treosulfan, Tremozolomide, Thiotepa, Daunorubicin, Doxorubicin, Aclarubicin, Epirubicin, Mitoxantrone, Idarubicin, Bleomycin, Mitomycin, Dactinomycin, Methotrexate, Fludarabine, Fludarabine-5 ' dihydrogen phosphate, mofebutazone, acemetacin, diclofenac, lonazolac daps on, o-carbamoylphenoxyacetic acid, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, chloroquine phosphate, penicillamine, hydroxychloroquine, auranofin, sodium aurothiomalate, oxaceprol, celecoxib, [beta] -sitosterol, ademetionin, myrtainaine, polidocanol, nonivamide, levomenthol, benzocaine, aescin, Cladribine Mercaptopurine Thioguanine Cytarabine Fluorouracil Gemcitabine Capecitabine Docetaxel Carboplatin Cisplatin Oxaliplatin Amsacrine Irinotecan Topotecan Hydroxycarbamide Miltefosine Pentostatin Aminoglutethemide, adriamycin, azithromycin, spiramycin, cepharantin, SMC proliferation inhibitor-2w, epothilones A and B, mitoxanthrones, azathioprine, mycophenolate mofetil, c-myc antisense, b-myc antisense selectin (cytokine antagonist) CETP inhibitor, cadherins, Cytokine inhibitors, COX-2 inhibitor, NFkB, angiopeptin, ciprofloxacin, camptothecin, fluroblastin, monoclonal antibodies containing the Inhibiting muscle cell proliferation, bFGF antagonists, probucol, prostaglandins, Folic acid and derivatives, vitamins of the B series, vitamin D derivatives such. As calcipotriol and tacalcitol, thymosin [alpha] -1, fumaric acid and its derivatives such. Dimethyl fumarate, IL-1 [beta] inhibitor, colchicine, NO donors such as pentaerythritol tetranitrate and syndnoeimines, S-nitrosated derivatives, tamoxifen, staurosporine, [beta] estradiol, [alpha] estradiol, estrone, estriol, ethinyl estradiol, fosfestrol , Medroxyprogesterone, estradiol cypionates, estradiol benzoates, tranilast, kamebakaurin and other terpenoids used in cancer therapy, verapamil, tyrosine kinase inhibitors (tyrphostins), cyclosporin A, paclitaxel and its derivatives (6- [alpha] -hydroxy-paclitaxel), Baccatin, taxotere, etc.), synthetically prepared and naturally derived macrocyclic oligomers of carbon suboxide (MCS) and its derivatives, molgramostim (rhuGM-CSF), peginterferon [alpha] -2b, lanograstim (r-HuG-CSF), filgrastim, Macrogol, dacarbazine, basiliximab, daclizumab, ellipticin, D-24851 (Calbiochem), colcemid, cytochalasin A-E, indanocine, nocadazole, S100 protein, PI-88, melanocyte stimulating hormone ([alpha] -MSH), bacitracin, vitronectin -Rezepto r antagonists, azelastine, guanidyl cyclase stimulator, metalloproteinase-1 and 2 tissue inhibitor, free nucleic acids, nucleic acids incorporated in virus carriers, DNA and RNA fragments, inhibitor-1 plasminogen activator, inhibitor-2 plasminogen activator, antisense oligonucleotides, VEGF Inhibitors, called IGF-1. Cefadroxil, cefazolin, cefaclor, cefotixine, tobramycin, gentamycin are also used in the group of antibiotics. Penicillins such as dicloxacillin, oxacillin, sulfonamides, metronidazole, antithrombotics such as argatroban, aspirin, abciximab, synthetic antithrombin, bivalirudin, coumadin, enoxoparin, hemoparin <(R)> (desulfated and N-reacetylated heparin) also have a positive influence on the postoperative period. Tissue plasminogen activator, GpIIb / IIIa platelet membrane receptor, factor Xa inhibitor, activated protein C, antibody, heparin, hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyramidol, trapidil, nitroprusside , PDGF antagonists such as triazolopyrimidine and seramin, ACE inhibitors such as captopril, cilazapril, lisinopril, enalapril, losartan, thioprotease inhibitors, caspase inhibitors, apoptosis inhibitors, apoptosis regulators such as p65, NF-kB and BcI-xL antisense oligonucleotides and prostacyclin, vapiprost, [ alpha], [beta] and [gamma] interferon, histamine antagonists, serotonin blockers, halofuginone, nifedipine, tocopherol, Trani rast, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, boswellic acids and their derivatives, leflunomide, anakinra, etanercept, sulfasalazine, etoposide, dicloxacylline, tetracycline, triamcinolone, mutamycin, procainimide, retinoic acid, quinidine, disopyrimide, flecainide, propafenone, sotolol, amidorone. Other drugs include steroids (hydrocortisone, betamethasone, dexamethasone), non-steroidal drugs (NSAIDS) such as fenoporfen, ibuprofen, indomethacin, naproxen, phenylbutazone and others. Antiviral agents such as acyclovir, ganciclovir and zidovudine are also useful. Various antimycotics find application in this area. Examples are clotrimazole, flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine. Antiprozoal agents such as chloroquine, mefloquine, quinine are equally effective agents, as well as natural terpenoids such as hippocaesculin, barringtogenol C21-angelate, 14-dehydroagrostistachine, agroscerin, agrostistachin, 17-hydroxyagrostistachine, ovatodiolides, 4,7-oxycycloanisomelic acid, baccharinoids B1, B2 , B3, Tubeimoside, Bruceanole A, B, C, Bruceantinoside C, Yadanzioside N, and P, Isodeoxyelephantopin, Tomenphantopin A and B, Coronarin A, B, C and D, Ursolic acid, Hyptate A, Zeorin, Iso-Iridogermanal, Maytenfoliol, Effusantin A, Excisanin A and B, Longikaurin B, Sculponeatin C, Kamebaunin, Leukamenin A and B, 13,18-Dehydro-6-alpha-Senecioyloxychaparrine, 1,11-Dimethoxycanthin-6-one, 1-Hydroxy-11-Methoxycanthin -6-one, scopolectin, taxamairin A and B, rainilol, triptolide, further cymarin, apocymarin, aristolochic acid, anopterin, hydroxyanopterin, anemonin, protoanemonin, berberine, cheliburine chloride, cictoxin, sinococulin, bastbrestatin A and B, cudraisoflavone A, Cu rcumin, dihydronitidine, nitidinium chloride, 12-beta-hydroxypregnadiene-4,16-diene 3,20-dione, bilobol, ginkgol, ginkgolic acid, helenaline, indicine, indicin-N-oxide, lasiocarpine, inotodiol, glycoside 1a, podophyllotoxin, justicidin A and B, Larreatin, Malloterine, Mallotochromanol, Isobutyrylmallotochromanol, Maquiroside A, Marchantin A, Maytansin, Lycoridicin, Margetin, Pancratistatin, Liriodenine, Oxoushinsunin, Aristolactam-AII, Bis-Parthenolidine, Periplocoside A, Ghalacinoside, Ursolic Acid, Deoxypicorospermine, Psycorubin, Ricin A, Sanguinarine , Manwuweizsäure, Methylsorbifolin, Sphatheliachromen, Stizophyllin, Mansonin, Streblosid, Akagerin, Dihydrousambaraensin, Hydroxyusambarin, Strychno-pentamin, Strychnophyllin, Usambarin, Usambarensin, Berberine, Liriodenin, Oxoushinsunin, Daphnoretin, Lariciresinol, Methoxylariciresinol, Syringaresinol, Umbelliferone, Afromoson, Acetylvismion B, Desacetylvismion A, Vismion A and B, other natural terpenoids such as Hippocaesculin, 14-Dehydroagrostistachin, C-Ty pe Natriuretic Peptide (CNP), Agroscerin, Agrostistachin, 17-Hydroxyagrostistachin, Ovatodiolide, 4,7-Oxycycloanisomic Acid, Yadanziosides N and P, Isodeoxyelephantopin, Tomenphantopin A and B, Coronarin A, B, C and D, Ursolic Acid, Hyptate Acid A , Zeorin, Iso-Iridogermanal, Maytenfoliol, Effusantin A, Excisanin A and B, Longikaurin B, Sculponeatin. Coating of carrier material on balloon catheter according to claim 1, characterized in that the TPGS NF, d-α-tocophery Polyethylene glycol materials are of both natural and synthetic or semi-synthetic origin. Coating of carrier material on balloon catheter with substances according to claim 1 and 2, characterized in that the TPGS NF, α-tocopherol polyethylene glycol belong to the following substance classes: monoterpenes, sesquiterpenes, diterpenes, sesterterpenes, triterpenes and tetraterpenes or mixtures thereof. Coating of carrier material on a balloon catheter according to claims 1 to 3, characterized in that the materials used other than the TPGS NF, α-tocopherol polyethylene glycol are of inorganic or organic origin. Coating of carrier material to balloon catheter according to claim 4, characterized in that the inorganic materials are oxides and / or salts. Coating of carrier material on balloon catheter according to claim 5, characterized in that they are phosphates, sulfates, silicates, carbonates or mixtures thereof. Coating of carrier material on balloon catheter according to claim 4, characterized in that the organic materials are lipids and their components. Coating of carrier material on balloon catheter according to claim 7, characterized in that the organic materials are carboxylic acids, their derivatives and substitution products. Coating of carrier material on balloon catheter according to claims 1 to 8, characterized in that the coating material TPGS NF, d-α-tocopherol contains polyethylene glycol. Coating of carrier material on balloon catheter according to claims 1 to 8, characterized in that the coating material contains rosin. Coating of carrier material on balloon catheter according to claims 1 to 8, characterized in that the coating material contains the resins dammar and / or mastic. Coating of carrier material on balloon catheter according to claims 1 to 8, characterized in that the coating material contains the component shelloleic acid. Coating of carrier material on balloon catheter according to claims 1 to 8, characterized in that the coating material contains the component abietic acid. Coating of carrier material on balloon catheter according to claim 1 to 13, characterized in that the carrier material has a layer thickness of 0.01 to 10.0 μg / mm ² . Coating of carrier material on balloon catheter according to claim 1 to 14, characterized in that the cytostatic (paclitaxel) has a concentration of 0.5 to 10.0 μg / mm ² on the carrier material. Coating of carrier material on balloon catheter according to claim 1 to 15, characterized in that the active substance (cytostatic agent, eg paclitaxel) has nanocrystalline properties. Coating of the carrier material according to the invention on stents.